Hrt Financial LP Atara Biotherapeutics, Inc. Transaction History

Hrt Financial LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.23 - $1.74 $26,971 - $204,044	117,267 New	117,267 $60,000
Q2 2023 Aug 11, 2023	BUY	$1.5 - $3.04 $242,893 - $492,264	161,929 New	161,929 $260,000
Q4 2022 Feb 10, 2023	SELL	$2.85 - $5.18 $258,118 - $469,142	-90,568 Reduced 66.93%	44,751 $146,000
Q3 2022 Nov 14, 2022	BUY	$2.85 - $8.73 $385,659 - $1.18 Million	135,319 New	135,319 $511,000
Q3 2021 Nov 15, 2021	SELL	$11.99 - $17.9 $207,846 - $310,296	-17,335 Closed	0 $0

Q2 2021 Aug 16, 2021	BUY	$12.89 - $16.58 $223,448 - $287,414	17,335 New	17,335 $269,000
Q1 2020 May 15, 2020	SELL	$5.69 - $17.78 $278,992 - $871,788	-49,032 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$10.89 - $16.79 $533,958 - $823,247	49,032 New	49,032 $807,000

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $728M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.